CompletedNot Applicable

Ceprotin Treatment Registry

United States43 participantsStarted 2010-06-23

Plain-language summary

The overall objective is to collect and assess data on the treatment, safety, and treatment outcomes of subjects prescribed, receiving and participating in the Ceprotin treatment registry.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Participants for whom CEPROTIN therapy has been indicated and meeting the following criteria may be enrolled in this study: * Signed and dated informed consent from either the participant or the participant's legally authorized representative prior to enrollment, as applicable * Males and females of any age, including neonates, children, adolescents and adults * Participant who received CEPROTIN or is initiating/receiving CEPROTIN treatment Exclusion Criteria: * None

What they're measuring

Medical diagnoses associated with Ceprotin treatment

Timeframe: 2 to 5 years, or until the Registry is terminated

Ceprotin treatment regimens

Timeframe: 2 to 5 years, or until the Registry is terminated

Safety information based on all serious adverse events (SAEs), related SAEs and related non-serious adverse events (AEs)

Timeframe: 2 to 5 years, or until the Registry is terminated

Trial details

NCT IDNCT01127529

SponsorBaxalta now part of Shire

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-06-22

View on ClinicalTrials.gov More Protein C Deficiency trials